Faculty Collaboration Database

CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma. Am J Clin Pathol 2012 Dec;138(6):867-76

Date

11/20/2012

Pubmed ID

23161721

DOI

10.1309/AJCP3TQR1TFHHGAS

Scopus ID

2-s2.0-84869234870 (requires institutional sign-in at Scopus site)   9 Citations

Abstract

The majority of plasma cell myelomas (PCMs) are positive for CD200, a membrane protein with immunosuppressive function. There are no flow cytometry data in the literature on plasma cell CD200 expression in other immunoproliferative disorders. Therefore we used flow cytometry to study the expression of CD200 on plasma cells in diagnostic bone marrow aspirates from 61 patients with monoclonal gammopathy of undetermined significance (MGUS) and 10 patients with lymphoplasmacytic lymphoma (LPL). For comparison, we evaluated CD200 expression in 74 PCM bone marrow biopsies. Thirty-three (54.1%) of 61 MGUS cases and 2 (20.0%) of 10 LPL cases were CD200+. Comparative clinicopathologic parameters for MGUS cases, based on CD200 expression status, showed no differences between the 2 groups. The proportion of CD200+ PCMs (73.0%) in our series was significantly higher than that of CD200+ MGUS (P = .030) and CD200+ LPL (P = .002) cases.

Author List

Olteanu H, Harrington AM, Kroft SH

Authors

Alexandra M. Harrington MD Professor in the Pathology department at Medical College of Wisconsin
Steven Howard Kroft MD Chair, Professor in the Pathology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Aged, 80 and over
Antigens, CD
Bone Marrow
Female
Flow Cytometry
Humans
Immunophenotyping
Immunoproliferative Disorders
Male
Middle Aged
Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma
Plasma Cells
Waldenstrom Macroglobulinemia